Acrivon Therapeutics Research Coverage Started at Maxim Group
| ACRV Stock | 1.13 0.07 5.83% |
Slightly above 66% of Acrivon Therapeutics,'s investor base is looking to short. The analysis of the overall investor sentiment regarding Acrivon Therapeutics, Common suggests that many traders are alarmed. Acrivon Therapeutics,'s investing sentiment can be driven by a variety of factors including economic data, Acrivon Therapeutics,'s earnings reports, geopolitical events, and overall market trends.
Maxim Group initiated coverage on shares of Acrivon Therapeutics in a research report released on Thursday morning, MarketBeat reports. The firm issued a buy rating and a 24.00 price objective on the stock. A number of other analysts have also recently weighed in on the stock. Jonestrading assumed coverage on shares
Read at thelincolnianonline.com
 |
Acrivon Therapeutics, Fundamental Analysis
We analyze Acrivon Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acrivon Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acrivon Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Acrivon Therapeutics, is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Acrivon Therapeutics, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Acrivon Therapeutics, stock to make a market-neutral strategy. Peer analysis of Acrivon Therapeutics, could also be used in its relative valuation, which is a method of valuing Acrivon Therapeutics, by comparing valuation metrics with similar companies.
Peers
Acrivon Therapeutics, Related Equities
| ANAB | AnaptysBio | 2.45 | ||||
| MLYS | Mineralys Therapeutics, | 1.20 | ||||
| ADAG | Adagene | 1.18 | ||||
| ANTX | AN2 Therapeutics | 0.84 | ||||
| PMVP | Pmv Pharmaceuticals | 1.16 | ||||
| RZLT | Rezolute | 1.61 | ||||
| ANEB | Anebulo Pharmaceuticals | 5.77 | ||||
| MOLN | Molecular Partners | 7.01 |
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.